amaxa eNews #5   Issue: amaxa eNews #1 amaxa eNews #2 amaxa eNews #3 amaxa eNews #4 amaxa eNews #5 Article: Overview Application Note Review Product Information Presentation Meetings & Shows Request more Info Related FAQs Related Citations FAQs on Nucleofection in Cancer Research Is it possible to transfect mRNA of tumor cells into antigen-presenting cells like B cells or dendritic cells with the Nucleofector Technology? Can I use the protocol for MCF7 cells for other breast cancer cell lines? Can I use nucleofection to create a stable knockdown in a cancer cell line? What protocol should I use for nucleofection® of patient derived blood samples, e.g. leukemia or lymphoma cells? Is it possible to transfect siRNA into blood cells from NHL patients? I have great efficiency for my cancer cell line with pmax-GFP but lower results with my construct. Do you have any suggestions on how to improve the efficiency? In your optimized protocols for MDA-MB-231 and MDA-MB-468, you say to culture the cells without CO2. Why? For more FAQs browse our FAQ database.        More Information If your question is not listed please do not hesitate to contact our Scientific Support Team:   Europe/World  USA   phone  +49(0)221-99199-400  (888) 632-9110   fax  +49(0)221-99199-499  (888) 632-9112   e-mail  scientific-support@amaxa.com  scientific-support.US@amaxa.com  Subscribe Subscribe here to receive future issues of amaxa eNews. Invite a friend Recommend amaxa's eNews to a friend or colleague. The Nucleofector Technology, comprising Nucleofection Process, Nucleofector Device, Nucleofector Solutions, Nucleofector 96-well Shuttle System and Nucleocuvette plates and modules is covered by patent and/or patent pending rights owned by amaxa AG. amaxa, Nucleofector, nucleofection, maxGFP, 96-well Shuttle and Nucleocuvette are either registered trademarks or trademarks of amaxa AG in the U.S. and/or Germany and/or other countries. Other product and company names mentioned herein are the trademarks of their respective owners. amaxa disclaims all warranties, whether expressed or implied, including any warranty as to the quality, accuracy, safety, or suitability of the information provided in this e-newsletter for any particular purpose. Any use of the information contained on any page of this e-newsletter is evidence of agreement with these terms of use.